At 6.7% CAGR, the North America Anatomic Pathology Market is Projected to be Worth US$ 21,398.45 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the North America anatomic pathology market was valued at US$ 12,692.48 in 2023 and is expected to reach US$ 21,398.45 million by 2031, registering a CAGR of 6.7% from 2023 to 2031. Increase in prevalence of cancer and kidney diseases and rise in number of strategic initiatives are among the critical factors attributed to the North America anatomic pathology market expansion.

Anatomic pathology is useful in identifying abnormalities that can help diagnose diseases, such as autoimmune diseases, kidney and liver diseases, and cancer. Histopathology, which involves studying tissue changes caused by diseases, is a vital part of anatomic pathology. Cancer has a major impact on society across the world. The burden of cancer on healthcare systems is significantly increasing worldwide as it is among the leading causes of death. The World Health Organization (WHO) ranks cancer as the second-leading cause of mortality worldwide. According to data published by the World Cancer Research Fund International, ~20 million new cases of cancer were registered in 2022 globally. Moreover, as per the data published by the World Health Organization (WHO), nearly 10 million deaths worldwide were caused by cancer in 2020. The National Center for Health Statistics data estimates that the diagnosis of new cancer cases in the US is likely to reach 2 million in 2024. In addition, ~0.61 million people are likely to die in 2024 in the US due to cancer.

The prevalence of chronic kidney disease is growing due to the increase in geriatric population. According to the Centers for Disease Control and Prevention, in 2023, ~35.5 million people in the US suffered from chronic kidney diseases. Biopsy, an anatomic pathology technique, is used for the detection of cancer and chronic kidney disease. Owing to the increasing prevalence of cancer and kidney disease, government agencies, healthcare providers, and institutions are being compelled to contribute toward disease diagnosis and treatment initiatives. Thus, a surge in the prevalence of cancer and other targeted diseases such as autoimmune diseases, kidney and liver diseases is driving the North America anatomic pathology market growth.

On the contrary, lack of skilled professionals hampers the growth of North America anatomic pathology market.

Based on product and services, the North America anatomic pathology market is segmented into services, instruments, and consumables. The instruments segment held 44.9% share of the North America anatomic pathology market in 2023, amassing US$ 5,692.90 million. It is projected to garner US$ 8,893.27 million by 2031 to expand at 5.7% CAGR during 2023–2031. The services segment is further sub segmented into histopathology and cytopathology. The instruments segment is further sub segmented into microtomes and cryostat, automatic stainer's, tissue processors, and others.

By application, the North America anatomic pathology market is segmented into disease diagnosis, drug discovery and development and others. The disease diagnosis segment held 64.9% share of the North America anatomic pathology market in 2023, amassing US$ 8,237.72 million. It is projected to garner US$ 14,705.48 million by 2031 to expand at 7.5% CAGR during 2023–2031.

By end user, the North America anatomic pathology market is segmented into hospitals, research laboratories, diagnostic laboratories, and others. The hospitals segment held 36.1% share of the North America anatomic pathology market in 2023, amassing US$ 4,584.19 million. It is projected to garner US$ 7,912.72 million by 2031 to expand at 7.1% CAGR during 2023–2031.

Based on country, the North America anatomic pathology market is segmented into the US, Canada, and Mexico. The US held 91.6% share of North America anatomic pathology market in 2023, amassing US$ 11,621.23 million. It is projected to garner US$ 19,707.70 million by 2031 to expand at 6.8% CAGR during 2023–2031.

Key players operating in the North America anatomic pathology market are F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Hologic Inc, Agilent Technologies Inc, BioGenex Laboratories Inc, Diapath S.p.A., Bio SB, Merck KGaA, and PHC Holdings Corporation, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com